Revlimid

Analyst: Trump's 'Naming And Shaming' Campaign To Build Pharma Headline Risk

Celgene CEO: Strong Q1 Led To Improved Full-Year Guidance

Upside And Downside Scenarios For Celgene; Is The Selloff Overdone?

Celgene CEO: Strong Q1 Led To Improved Full-Year Guidance

Upside And Downside Scenarios For Celgene; Is The Selloff Overdone?

As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked?

Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?

As Celgene Outperforms, Are Challenges To Its Pipeline Being Overlooked?

|

Has Celgene Become Vulnerable To 'Revenue Concentration Risk'?

|

Couldn't Make It To Leerink's Global Healthcare Conference? Here Are The Highlights From Day One

|

Orphan Drugs Among 2015's Top 10 Best-Selling Medications

|

Revlimid Recent News

Biotech Winners And Losers From ASH Conference

|

Amgen's Kyprolis Fails To Met Endpoint, But It's Not All Bad News

|

Celgene Reports Second-Quarter Results, Highlights 'Outstanding' 2016 Performance

|

Celgene To See Major Upside In 2017, Says Canaccord

|

Celgene Will 'Vigorously' Defend IP Amid Report Kyle Bass Patent Challenge Could Prove Successful

|

Celgene's EPS Contain 'Few Surprises,' Baird Says

|